| Literature DB >> 30988789 |
Wenbo Li1, Xinyu Fang1, Chaofan Zhang1,2, Yejun Xu1, Zida Huang1, Zibo Yu1, Wenming Zhang1.
Abstract
Septic hip arthritis is a rare but serious disease, which is often persistent, able to transform into a chronic infection, and difficult to cure. The present study aimed to compare the midterm outcomes between the staging of a total hip arthroplasty via the Girdlestone surgery (a resection of the head and neck) and the Girdlestone combined with a cement spacer in treating chronic septic hip arthritis, as well as to compare the postsurgery efficacy and complications between the two groups. A total of 13 patients (14 total hip joints) were enrolled and retrospectively analyzed. For the stage I surgery, four patients (five hips) underwent the resection of the head and neck, and nine patients (nine hips) underwent the resection of the head and neck combined with the implantation of a bone cement spacer. After the infection was fully controlled, the patients in both groups underwent cementless total hip arthroplasties as stage II surgeries. The mean follow-up period was 24.2 months. The curative effects and complications of the patients were recorded and compared. It was found that the application of the staging arthroplasty for treating a chronic septic hip was conducive to the complete clearance of lesions. Notably, the implantation of a bone cement spacer containing antibiotics in the stage I surgery prevented joint contracture caused by a head and neck resection, reducing the risk of infection recurrence between the two stages of the operation. This effectively maintained the length of the lower limbs, simplified the stage II complete hip arthroplasty and reduced operative hemorrhage, thus achieving improved recovery of joint function after the stage II arthroplasty. The results suggested that the implantation of a cement spacer at the stage I surgery was more effective in treating chronic septic hip arthritis.Entities:
Keywords: bone cement spacer; hip joint infection; septic arthritis; two-stage arthroplasty
Year: 2019 PMID: 30988789 PMCID: PMC6447925 DOI: 10.3892/etm.2019.7430
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Figure 1.Images of a patient receiving a femoral head and neck resection (case 1). (A) Male, 59 years old with bilateral hip joint pain and sinus present for 3 months, no improvement after receiving I&D and an antibiotic treatment. (B and C) The patient successively underwent resection of the head and neck of the left and right hips. Culture results revealed the presence of Burkholderia pseudomallei. After the surgery, the CRP did not decline to the normal level for a long period of time and the patient received prolonged course of antibiotics. (D) After 1 year the CRP returned to a normal level, the patient successively underwent a left and right total hip arthroplasty. During the operation it was found that soft tissue surrounding the hip joint was difficult to loosen; a large amount of scar hypertrophy and a severe operative hemorrhage were observed in the acetabulum. The postoperative bilateral lower limbs were shortened, and the hip joints had poor range of motion. CRP, C-reactive protein; I&D, incision and debridement.
Figure 2.Images of a patient undergoing a femoral head and neck resection and spacer treatment (Case 5): (A) Male, 62 years old, pain for 3 months after the surgical treatment of a left acetabulum fracture, with purulence found in I&D and no improvement observed after receiving antibiotics. (B) The patient underwent a head and neck resection and an implantation of a bone cement spacer after the internal fixation was removed. (C) The infection was controlled after 3 months, and the patient underwent a hip arthroplasty, with a lower degree of operative hemorrhage. After the surgery, the lengths of the lower limbs were recovered and the hip joints had a good range of motion.
Figure 3.A small cement prosthetic was used as a skeleton to fabricate a spacer (case 6). (A) A spacer mold and (B) a fabricated spacer using a cement prosthesis as the skeleton was implanted into the body.
Pathogen and stage I surgery.
| Case | Type of stage 1 surgery | Pathogen | Antibiotics administration after stage 1 (IV) | Length of antibiotic therapy after stage 1 (weeks) | Interval to normal CRP (weeks) | Interval to THA (months) |
|---|---|---|---|---|---|---|
| 1 | Girdlestone | Burkholderia pseudomallei | Meropenem Ceftazidime | L-24 | L-12 | L-12 |
| R-10 | R-7 | R-9.5 | ||||
| 2 | Girdlestone | Stenotrophomonas maltophilia | Meropenem | 12 | 12 | 33 |
| 3 | Girdlestone | Levofloxacin | 8 | 6 | 69 | |
| 4 | Girdlestone | MRSA | Vancomycin | 6 | 5 | 24 |
| 5 | Spacer | Enterobacter cloacae | Meropenem | 6 | 4 | 3 |
| 6 | Spacer | Corynebacterium | Vancomycin meropenem Cefoperazone | 8 | 6 | 5.5 |
| 7 | Spacer | Negative | Vancomycin moxifloxacin | 8 | 4 | 4.5 |
| 8 | Spacer | Streptococcus | Vancomycin levofloxacin | 8 | 4 | 3 |
| 9 | Spacer | MSSA | Vancomycin cefuroxime | 6 | 4 | 4 |
| 10 | Spacer | Negative | Vancomycin levofloxacin | 12 | 12 | 3 |
| 11 | Spacer | MRSA | Vancomycinlinezolid | 12 | 10 | 3 |
| 12 | Spacer | MSSA | Vancomycin | 6 | 3 | 4 |
| 13 | Spacer | MSSA | Vancomycin | 6 | 5 | 6 |
L, left; R, right; CRP, C-reactive protein; THA, total hip arthroplasty; MRSA, Methicillin-resistant Staphylococcus aureus; MSSA, Methicillin-susceptible Staphylococcus aureus.
Patient data (preoperative).
| Case | Age (years)/Sex | Cause of presentation | Duration of symptom (days) | Joint | Etiology | Comorbidities | Previous treatment for infection |
|---|---|---|---|---|---|---|---|
| 1 | 59/M | Pain, sinus | L-60; R-35 | Bilateral | Primary | Syphilis, osteoporosis | I&D, Cefradine |
| 2 | 54/M | Pain | 106 | Left | Primary | Gout | Aspiration |
| 3 | 61/M | Pain, sinus | 120 | Right | Femoral neck fracture ORIF | Eczema | I&D, Cefdinir |
| 4 | 67/M | Pain | 125 | Right | Primary | NIDDM | None |
| 5 | 62/M | Pain | 71 | Left | Acetabula fracture ORIF | Arterial hypertension, NIDDM | I&D, Moxifloxacin |
| 6 | 52/M | Sinus | 63 | Right | AVN focal cleaning | Cirrhosis | Cefradine |
| 7 | 55/M | Pain, sinus | 61 | Right | Femoral neck fracture ORIF | None | I&D, Cefradine |
| 8 | 77/F | Pain | 64 | Right | Femoral neck fracture ORIF | Arterial hypertension, NIDDM, PD | Cefdinir |
| 9 | 49/F | Pain | 123 | Left | Primary | None | Cefradine |
| 10 | 75/F | Pain | 100 | Right | Primary | None | Cefradine |
| 11 | 79/F | Pain | 60 | Left | Primary | None | None |
| 12 | 62/M | Pain | 90 | Right | Primary | NIDDM | None |
| 13 | 19/F | Pain | 80 | Right | Femoral neck fracture ORIF | None | Cefradine |
AVN, Avascular necrosis; F, female; I&D, incision and debridement; M, male; NIDDM, non-insulin-dependent diabetes mellitus; L, left; R, right; ORIF, open reduction internal fixation.
Patient data (stage II surgery and postoperative implications).
| Case | Operative hemorrhage of THA (ml) | Duration of THA operation (min) | Leg-length discrepancy after THA (cm) | Preoperative hip score | Interim hip score | Final hip score | Complication between stages | Complication after prosthesis implantation | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | L-200 | L-90 | L-2.0 | L-54 | L-74 | L-82 | 62 | ||
| R-400 | R-120 | R-2.2 | R-52 | R-72 | R-81 | ||||
| 2 | 500 | 150 | 2.2 | 51 | 75 | 84 | Pneumonia, hematosepsis, poor wound healing | Poor wound healing | 27 |
| 3 | 600 | 100 | 5.0 | 49 | 66 | 83 | Recurrence of infection, poor wound healing | Poor wound healing | 24 |
| 4 | 805 | 160 | 3.0 | 65 | 78 | 12 | |||
| 5 | 250 | 90 | 1.1 | 47 | 85 | 90 | 24 | ||
| 6 | 600 | 105 | 2.0 | 48 | 79 | 89 | Pneumonia, type-I respiratory failure | 28 | |
| 7 | 200 | 70 | 1.0 | 53 | 85 | 93 | 36 | ||
| 8 | 300 | 80 | 0.8 | 30 | 90 | 91 | Spacer fracture | 30 | |
| 9 | 200 | 147 | 0.7 | 45 | 91 | 84 | 16 | ||
| 10 | 150 | 115 | 0 | 35 | 75 | 78 | 17 | ||
| 11 | 500 | 116 | 1 | 42 | 79 | 94 | 13 | ||
| 12 | 500 | 127 | 0 | 20 | 95 | 93 | 14 | ||
| 13 | 200 | 100 | 0.5 | 25 | 88 | 88 | 12 |
L, left; R, right; THA, total hip arthroplasty.
Comparison of the two surgical procedures.
| Surgical type | Operative hemorrhage of THA (ml) | Duration of THA operation (min) | Leg-length discrepancy after THA (cm) | Preoperative Harris hip score | Interim Harris hip score | Final Harris hip score |
|---|---|---|---|---|---|---|
| Girdlestone alone | 501.0±100.8 | 124.0±13.6 | 2.8±0.6 | 47.8±2.5 | 70.4±2.1 | 81.6±1.1 |
| Girdlestone + spacer | 322.2±55.4 | 105.6±7.9 | 0.8±0.2 | 40.7±3.1 | 85.2±2.2 | 88.9±1.7 |
| P-value | 0.1658 | 0.2812 | 0.0015 | 0.1783 | 0.0020 | 0.0175 |
THA, total hip arthroplasty.